Medicine and Cytometry Service (NUCLEUS), University of Salamanca (USAL) and Institute for ... to evaluate the AML heterogeneity expression in the different blast cell subpopulations detected at ... Email address: [email protected].
Abstract Submission 3. Acute myeloid leukemia - Biology ABSSUB-6084 IMPACT OF IMMATURE MARKERS BY FLOW CYTOMETRY IN LEUKEMIC BLAST CELL HETEROGENEITY AML María Concepción García-Dabrio* 1, Montserrat Hoyos2, Salut Brunet3, Mar Tormo4, Josep-Maria Ribera5, Jordi Esteve6 , David Gallardo7, Rafael F Duarte8, Maria Paz Queipo de Llano9, Josep M. Martí-Tutusaus10, Olga Salamero11, Alberto Orfao12, Jorge Sierra2, Josep F Nomdedeu1 1Department of Hematology and Laboratory, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 2 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, 3 Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Universitat Autònoma de Barcelona, Barcelona, 4Department of Hematology, Hospital Clínic, Valencia, 5Department of Hematology, Department of Hematology, Hospital ICO Germans Trias i Pujol, Badalona, Badalona, 6Department of Hematology, Department of Hematology, Hospital Clínic, IDIBAPS, Barcelona, 7Department of Hematology, Hospital ICO Hospital Josep Trueta, Girona, Girona, 8Department of Hematology, Hospital ICO Duran i Reynalds, L´Hospitalet, Barcelona, L´Hospitalet, Barcelona, 9Department of Hematology, Department of Hematology, Hospital Virgen de la Victoria, Malaga, Spain., Malaga, 10Department of Hematology, Hospital de la Mutua de Terrassa, Terrassa, 11Department of Hematology, Hospital de la Vall d' Hebrón, Barcelona,, Barcelona, 12Cancer Research Center (IBMCC, USAL-CSIC), Department of Medicine and Cytometry Service (NUCLEUS), University of Salamanca (USAL) and Institute for Biomedical Research of Salamanca (IBSAL), Salamanca, Spain Please indicate your presentation preference: Poster Presentation Background: Acute myeloid leukemia (AML) is a heterogeneous disease, often characterized by coexistence of more than one subpopulation of blast cells with different immunophenotypes. Aims: The aim of our study was to evaluate the AML heterogeneity expression in the different blast cell subpopulations detected at diagnosis in a group of 151 adult de novo AML patients (pts) (M3 excluded) by multiparametric flow cytometry (MFC). Methods: We analyzed the prognostic impact of percentage of positive cells (%) and mean fluorescence intensity (MFI) expression of several immaturity cell surface markers (CD34, CD117, CD7, and CD123) on leukemic blasts by MFC treated according to the multicenter CETLAM AML-03 protocol (clinicaltrials.govNCT01723657). We also determined its correlation with other clinical and biological variables and the prognostic significance in terms of overall survival (OS), leukemia-free survival (LFS) and cumulative incidence of relapse (CIR) in the whole AML series, and latter focussing on clinico-biological characteristics of 151 heterogeneously AML cases using plots displaying data in a 3D density to better assignement blast intraleukemia heterogeneity. Results: CD34+ measured as the percentage (≥2.88%) and MFI (≥284, arbitrary units (a.u.)) expression had prognostic impact in terms of OS (P=0.005, P=0.003), LFS (P=0.011, P
